Bristol-Myers Squibb Co
We’re looking to further trim this drug stock and exit this entertainment giant
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. The S & P 500 turned higher Friday. The index opened lower after posting its worst one-day performance since Oct. 10. Still, Wall Street remains cautious of Big Tech’s […]
Read More
Stocks making the biggest moves midday: Cigna, FormFactor, Meta Platforms, Microsoft, Carvana & more
Check out the companies making the biggest moves midday: Cigna — Shares of the health insurance company after management said during an earnings call that it expects its pharmacy benefit services division to face margin pressure in the next few years. Cardinal Health — The drug and medical equipment distributor surged more than 12% on […]
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]
Read More
Forget Trump’s tariffs — here’s what is separating pharma’s winners and losers
The pharmaceutical industry has been making headlines recently, after the administration of U.S. President Donald Trump slapped 100% tariffs on branded and patented drugs But investors say drugmakers’ carve-out agreements on pricing is what will rattle the sector — and create a range of winners and losers as a result. Global pharmaceutical companies who have broken […]
Read More
Trump’s drug price ultimatum sets pharma firms scrambling
Key Points A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday. President Trump sent letters to 17 major firms outlining the steps they must take to cut costs. Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump’s amended tariffs. Pharmaceutical firms are scrambling to respond […]
Read More